These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11329406)

  • 1. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.
    Schäfer M; Rujescu D; Giegling I; Guntermann A; Erfurth A; Bondy B; Möller HJ
    Am J Psychiatry; 2001 May; 158(5):802-4. PubMed ID: 11329406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further evidence of a dose-response threshold for haloperidol in psychosis.
    Stone CK; Garve DL; Griffith J; Hirschowitz J; Bennett J
    Am J Psychiatry; 1995 Aug; 152(8):1210-2. PubMed ID: 7625474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.
    Giegling I; Balzarro B; Porcelli S; Schäfer M; Hartmann AM; Friedl M; Konte B; Krämer P; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    Eur Arch Psychiatry Clin Neurosci; 2013 Feb; 263(1):65-74. PubMed ID: 22893251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
    Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Otani K; Furukori H; Kaneko S; Inoue Y
    Eur Arch Psychiatry Clin Neurosci; 2001; 251(2):57-9. PubMed ID: 11407439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antagonism of amphetamine-induced symptomatology by a neuroleptic.
    Angrist B; Lee HK; Gershon S
    Am J Psychiatry; 1974 Jul; 131(7):817-9. PubMed ID: 4600629
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
    J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
    Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
    Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
    Kang SG; Na KS; Lee HJ; Chee IS; Lee K; Lee J
    J Clin Psychopharmacol; 2015 Apr; 35(2):158-62. PubMed ID: 25679126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
    Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
    Wu S; Xing Q; Gao R; Li X; Gu N; Feng G; He L
    Neurosci Lett; 2005 Mar; 376(1):1-4. PubMed ID: 15694263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.